Business
DGAP-News: Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe
DGAP-News: Todos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n\n\n\n\nDGAP-News: Todos Medical, Ltd\n\n\n / Key word(s): Agreement\n\n\n\n\n\nTodos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe \n\n\n\n\n\n\n24.11.2021 / 08:00 \n\n\n\nThe issuer is solely responsible for the content of this announcement.\n\nTodos Medical Announces Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. for Tollovid(R) Products Covering 30 Countries in Europe\n\n- The agreement calls for a minimum of 500,000 bottles in sales over 18 months\n\n- T-Cell Protect to invest 1 million euros in Todos to support development of Tollovir, the Company's 3CL Protease Inhibiting Antiviral Drug Candidate\n\nNew York, NY, and Tel Aviv, ISRAEL - via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, together with its joint venture partner NLC Pharma, Ltd., today announced that it has entered into an exclusive European licensing & distribution agreement with T-Cell Protect Hellas S.A. (T-Cell Protect or T-Cell) for a product based on its Tollovid(R) and Tollovid Daily(TM) 3CL protease inhibitor and immune support dietary supplements. The product will be marketed under the T-Cell Protect brand throughout 30 countries in Europe with the agreement calling for a minimum of 500,000 bottles in sales over 18 months. T-Cell has placed an initial purchase order for 50,000 bottles of the Tollovid Daily product that is expected to meet the demand of an initial rollout to a subset of the 11,000 stores located throughout Greece. More information about the product can be found at www.tcellprotect.com. Under the terms of the agreement, T-Cell Protect will purchase finished product at wholesale from Todos until such time as T-Cell Protect establishes manufacturing capabilities at a facility it currently operates in Greece to support the European market. At such time, Todos will then receive double-digit royalties on the sales of the licensed product manufactured by T-Cell Protect. The Company anticipates revenue to be generated from this agreement beginning in the current quarter.\n\nConcurrent with this announcement, T-Cell Protect has made an investment of 1 million euros in Todos Medical to support the clinical development of Tollovir,...